We are live on
!
Find out more
BCM
BML Capital Management Portfolio holdings
AUM
$156M
1-Year Est. Return
129.82%
This Fund
S&P 500
This Quarter
Est. Return
+17.96%
1 Year Est. Return
+129.82%
3 Year Est. Return
+394.84%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$152M
AUM Growth
+$19.6M
(+15%)
Cap. Flow
+$8.22M
Cap. Flow
% of AUM
5.42%
Top 10 Holdings %
Top 10 Hldgs %
79.7%
Holding
38
New
3
Increased
11
Reduced
8
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Aclaris Therapeutics
ACRS
|
+$10.4M |
| 2 |
ADVM
Adverum Biotechnologies
ADVM
|
+$5.74M |
| 3 |
Instil Bio
TIL
|
+$3.82M |
| 4 |
PMV Pharmaceuticals
PMVP
|
+$2.44M |
| 5 |
OKUR
OnKure Therapeutics
OKUR
|
+$1.42M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TRML
Tourmaline Bio
TRML
|
+$6.43M |
| 2 |
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
|
+$4.49M |
| 3 |
LONA
LeonaBio Inc
LONA
|
+$1.76M |
| 4 |
RAIN
Rain Oncology Inc. Common Stock
RAIN
|
+$1.62M |
| 5 |
Oramed Pharmaceuticals
ORMP
|
+$1.17M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 67.15% |
| 2 | Technology | 1.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
VistaGen Therapeutics
VTGN
$9.98M
| $792K | 0.52% |
150,000
| – | – |
|
27
NextCure
NXTC
$20.4M
| $683K | 0.45% |
25,539
| – | – |
|
28
CalciMedica
CALC
$11.7M
| $667K | 0.44% |
160,424
+15,000
| +10% | +$68.5K |
|
29
PUT
Abercrombie & Fitch
ANF
$4.55B
| $470K | 0.31% |
100
-800
| -89% | -$91.2K |
|
30
Q32 Bio
QTTB
$435M
| $424K | 0.28% |
24,894
-16,668
| -40% | -$230K |
|
|
TLIS
31
DELISTED
Talis Biomedical Corporation Common Stock
TLIS
| $374K | 0.25% |
42,743
| – | – |
|
|
KLRS
32
Kalaris Therapeutics
KLRS
$80.9M
| $151K | 0.1% |
+8,716
| New | +$142K |
|
33
PUT
Build-A-Bear
BBW
$445M
| – | – |
-1,500
| Closed | -$465K |
|
34
Neurogene
NGNE
$672M
| – | – |
-24,666
| Closed | -$478K |
|
35
PUT
Invesco QQQ Trust
QQQ
$436B
| – | – |
-300
| Closed | -$661K |
|
|
TRML
36
DELISTED
Tourmaline Bio
TRML
| – | – |
-245,500
| Closed | -$6.43M |
|
|
THRX
37
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
| – | – |
-1,108,320
| Closed | -$4.49M |
|
|
RAIN
38
DELISTED
Rain Oncology Inc. Common Stock
RAIN
| – | – |
-1,349,007
| Closed | -$1.62M |
|
Similar funds
AIS
BWM
CFG
BCM
PMSA
GSWA
SPM
MCA
BML Capital Management's Q1 2024 Portfolio in Review
As of Q1 2024, BML Capital Management held 38 positions worth $152M, up 15% from $132M the previous quarter. Its ten largest holdings account for 80% of the portfolio.
BML Capital Management deployed $8.22M of net new capital in Q1 2024, opening 3 new positions and adding to 11 existing holdings. Its largest new stake was Instil Bio: 348,735 shares worth $3.77M.
By sector, the portfolio is most concentrated in Healthcare at 67% of assets, up from 60% a quarter earlier, followed by Technology.
On the sell side, the largest reduction was LeonaBio Inc, an estimated $1.76M trimmed.
- BML Capital Management's largest Q1 2024 buy was Instil Bio: 348,735 shares worth $3.77M.
- BML Capital Management added most to Aclaris Therapeutics in Q1 2024, an estimated $10.4M increase.
- BML Capital Management's biggest Q1 2024 reduction was LeonaBio Inc, cutting an estimated $1.76M.
- BML Capital Management fully exited Tourmaline Bio in Q1 2024, selling an estimated $6.43M.
- BML Capital Management's ten largest holdings make up 80% of its $152M portfolio in Q1 2024.
- BML Capital Management opened 3 new positions and closed 6 in Q1 2024.
- BML Capital Management's portfolio value rose 15% quarter-over-quarter to $152M.
Based on BML Capital Management's 13F filing for Q1 2024, filed 23 Apr 2024.